reluctant to provide specific and practical recommendations regarding early treatment because of the lack of large randomized, controlled, clinical trials in this area. The Heart Failure Society of America and the European Society of Cardiology (endorsed by the European Society of Intensive Care Medicine) guidelines provide some recommendations for acute heart failure, but many of them are categorized as level of evidence C, recognizing the paucity of available clinical trial data supporting the recommendations (6, 7) . Experts in cardiology, emergency medicine, and intensive care medicine from Europe and the United States convened in June 2006 to develop practical recommendations on the prehospital and early management of AHFS. The multidisciplinary and international nature of this group enhances the applicability of these recommendations. Data now exist to support the hypothesis that early and aggressive treatment in the first 6 -12 hrs after presentation may result in more favorable outcomes. Thus, we believed that detailed and practical guidance on patient management during this early phase would be useful to practicing physicians. These practical recommendations are not intended to replace existing guidelines. Rather, they are meant to serve as a tool to facilitate guideline implementation where data are available and to provide suggested treatment approaches by recommendations of an expert panel where formal guidelines and definitive evidence are lacking.
Rationale for Early Treatment of AHFS

Group Recommendation
• All AHFS patients should have the appropriate, goal-directed treatment started as early as possible. In some healthcare settings, this may occur either at home or in the ambulance. There is no contraindication to this concept.
ADHERE registry data indicate that AHFS treatments are often instituted Ͼ8 hrs after presentation. The mean time to intravenous diuretics was 8.1 hrs, and the mean time to intravenous vasoactive therapy was 22.8 hrs (8, 9) . The pathophysiologic mechanisms associated with AHFS, including activated neurohormones, increased filling pressure, or ischemia, may have deleterious effects on clinical outcomes (10) . Early initiation of appropriate therapy may be a method to counteract these negative effects before irreversible damage has occurred.
Randomized controlled trials that compare early and delayed therapy initiation in AHFS are lacking. However, in some patients with life-threatening conditions (i.e., pulmonary edema or cardiogenic shock), the need for immediate treatment is obvious. In addition, retrospective analyses of AHFS registry databases and studies performed in other acute illnesses suggest that early treatment initiation may be associated with improved outcomes.
A retrospective analysis from ADHERE evaluated the association between clinical outcomes and time to initiation of vasoactive therapy (11, 12) . The authors observed a nearly even distribution of patients who received vasoactive agents in the emergency department (ED) (n ϭ 4,096) compared with the inpatient unit (n ϭ 3,499). The mean time to vasoactive therapy initiation was 1-2 hrs when it was initiated in the ED compared with 20 -22 hrs when it was given after admission. Early administration in the ED was associated with a shorter median hospital length of stay (4.5 days vs. 7 days, p Ͻ .0001) and a lower in-hospital mortality rate (4.3% vs. 10.9%, p Ͻ .0001) (11) .
Nguyen et al. (13) prospectively studied the impact of ED intervention on physiologic scores in 81 patients who presented to the ED with illnesses severe enough to warrant intensive care unit (ICU) admission. The data from this study indicated that ED intervention may have influenced the progression of critical illnesses. A similar study in patients with severe sepsis or septic shock also demonstrated improved clinical outcomes with early goal-directed therapy (14) .
These data and others suggest that early initiation of treatments for AHFS may be a key factor in improving outcomes among critically ill patients (14, 15) . Randomized, controlled trials are needed to fully explore this hypothesis.
Management of AHFS Primarily Based on Systolic Blood Pressure
The European Society of Cardiology guidelines were the first to classify patients with AHFS into distinct clinical conditions (7) . These include a) acute decompensated heart failure, de novo or decompensated chronic heart failure; b) hypertensive acute heart failure; c) pulmonary edema; d) cardiogenic shock; e) high output failure; and f) right heart failure (7). However, this classification is a mixture of the clinical phenotype and disease severity on presentation, and there is significant overlap among the different conditions.
Prehospital and early ED and ICU/ critical care unit (CCU) management of AHFS is primarily based on signs and symptoms. Systolic blood pressure (SBP) was recently seen as the most important predictive factor of morbidity and mortality (16, 17) . We therefore proposed an algorithm primarily based on SBP at presentation and also on the existence of acute coronary syndrome (ACS) and/or right ventricular failure ( Table 1) .
As discussed later in this article, targeted treatment strategies differ among these clinical scenarios (Fig. 1) . Thus, although AHFS is a continuum, early patient classification is a key factor in determining the most appropriate initial therapy, and it may enable patients to receive goal-directed therapy more rapidly. This classification also facilitates early risk stratification of AHFS patients.
The SBP cutoffs proposed in this document have not been definitively established, but they were chosen from a consensus among experts and based on published literature (16) . At SBP of Ͼ140 mm Hg, left ventricular systolic function is likely preserved, at SBP of 100 -140 mm Hg left ventricular systolic function is limited, and many patients with impaired left ventricular systolic function exhibit SBP Ͻ100 mm Hg. Indeed, clinical judgment is extremely important for the management of all patients with AHFS.
Clinical Scenario 1 (CS1): Dyspnea and/or Congestion With Elevated SBP (Ͼ140 mm Hg).
In this scenario, symptoms typically develop abruptly. Dyspnea is primarily related to diffuse pulmonary edema, and minimal systemic edema is present. Patients are often systemically euvolemic or hypovolemic because of a long-lasting history of increased blood pressure and chronic treatment with diuretics. This clinical scenario is characterized by an acute elevation of filling pressures that parallels the increase in blood pressure and relatively preserved left ventricular ejection fraction in many patients (16, 18) . Compared with patients with lower SBP, CS1 patients also have ischemic heart disease less often, higher levels of serum creatinine, and a better prognosis in terms of intubation rate and short-term mortality (16 (19) . Pulmonary hypertension may be a contributing factor, and tricuspid regurgitation may be noted in the physical examination. These patients may have left-sided hypovolemia due to inappropriately large loop diuretic doses. EMS systems differ around the world. The available personnel include emergency medical technicians, paramedics, nurses, and physicians. The training level of personnel, availability of diagnostic equipment, and ability to administer treatments also vary among countries. These recommendations should be applied according to the locally available resources.
Prehospital Management of AHFS
The initial step in the prehospital management of AHFS is to establish the clinical diagnosis and to define the patient's clinical scenario based on presentation characteristics. The clinical assessment should include risk factor evaluation, past and recent medical history, current medications, symptoms, and physical examination. All personnel should be able to assess blood pressure, heart rate, and respiratory rate.
Where available, oxygen saturation should be determined. In some locations, (20 -23) .
In conjunction with establishing the clinical diagnosis, arrangements should be made to transport the patient to the nearest hospital with a cardiology service and a CCU. Cardiac catheterization laboratory facilities are also desirable for patients with an ACS. However, in some countries, EMS regulations require that the patient be transported to the nearest hospital, regardless of the available services. The consensus group discourages this practice and suggests that whenever possible, patients with heart failure and ACS should be immediately transported to a hospital with adequate intensive care facilities.
Diagnostic Assessments and Vital Sign/Hemodynamic Monitoring
Group Recommendation • Noninvasive monitoring, including arterial oxyhemoglobin saturation, blood pressure, respiratory rate, and continuous ECG, should be started within minutes of admission or in the ambulance if possible.
• Urine output should be measured as frequently as possible; no catheter is needed.
• ECG data should be gathered at admission for all patients.
• Radiograph should be performed at admission for all patients.
• Echocardiography should be performed at the earliest appropriate time according to the clinical scenario and individual patient need.
• Monitoring of cardiac output and filling pressures, for instance with a pulmonary artery catheter, is suggested in hemodynamically unstable patients who are not responding in a predictable fashion to traditional treatments or who are refractory to initial therapy, who have a combination of congestion and hypoperfusion, whose volume status and cardiac filling pressures are unclear, or who have clinically significant hypotension and worsening renal function during therapy (6, 7).
•Non-invasive monitoring (SaO 2 , BP, temperature) Symptomatic improvement is the focus on treatment during the first few hours after AHFS presentation. Therapy should be based on the specific clinical scenario. Because early treatments are symptom focused, invasive monitoring usually is not necessary within the first hours. In CS3 patients, if symptomatic treatments fail to restore SBP and perfusion within 90 mins, invasive monitoring and CCU/ICU admission is usually indicated. Patients presenting with concomitant acute coronary syndrome (CS4) should receive early treatments for ACS as indicated.
Admission Laboratory Analysis
Group Recommendation
The following laboratory assessments should be performed at admission in AHFS patients: The following assessments should be performed at admission in patients with CS1 or CS2:
• BNP or N terminal-pro-BNP can improve the diagnostic accuracy of AHFS and rule out pulmonary causes when added to standard clinical judgment.
In a patient presenting with dyspnea, BNP Ͻ100 pg/mL or NT-pro-BNP Ͻ300 pg/mL decreases the likelihood of an AHFS diagnosis, while BNP Ͼ500 pg/mL (25) or NT-pro-BNP Ͼ450 pg/mL in patients Ͻ50 yrs of age, Ͼ900 pg/mL in patients 50 -75 yrs of age, and Ͼ1800 pg/mL if age is Ͼ75 yrs (26) are likely indicators of AHFS.
Noninvasive Ventilation (NIV)
Group Recommendation • NIV should be used as early as possible in all AHFS patients when dyspnea, respiratory distress, and/or pulmonary edema are present to prevent the need for intubation and its subsequent complications and, potentially, to reduce the risk of mortality.
• NIV should never be used when there is a need for emergent intubation. NIV has a number of theoretical advantages, making it an attractive therapy for the early treatment of AHFS. It augments cardiac output, decreases left ventricular afterload, increases functional residual capacity and respiratory mechanics, and can reduce the work of breathing.
A total of 23 clinical trials have assessed the comparison between either CPAP and standard therapy (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) , Bi-PAP and standard therapy (28, 33, 34, 39 -42) , or CPAP and BiPAP (28, 33, 34, (43) (44) (45) (46) (47) (48) (49) . Two meta-analyses of these studies have recently been published and showed similar results. The first revealed that both CPAP and BiPAP reduce the need of intubation, but only CPAP reduces mortality in patients with acute cardiogenic pulmonary edema (50) . The second showed that CPAP reduced the need for mechanical ventilation and mortality when compared with standard therapy (51) . BiPAP led to a reduction in the need for mechanical ventilation and a nonsignificant reduction in mortality when compared with standard therapy. Similar findings were reported in another meta-analysis by Winck et al. (52) . In this analysis, CPAP was associated with a 22% absolute risk reduction in the need for intubation and a 13% absolute risk reduction in mortality. Some risk factors for intubation have been described in patients treated with conventional therapy: severe acidosis (pH Ͻ7.25), hypercapnia, acute myocardial infarction, low blood pressure, and severely depressed ventricular function (24) .
Based on these data, early use of NIV should be considered for the early management of all AHFS patients. NIV requires minimal nursing resources; however, patient cooperation is necessary. Generous use of morphine together with clear instructions may enhance patient adaptation to the technique. Surveys indicate that loop diuretics are the first-line agent around the world for the treatment of patients with AHFS. Furosemide is the most common loop diuretic used in clinical practice.
Diuretics
Group Recommendation
It is important to recognize two key points related to diuretic therapy. First, the widespread use of diuretics is largely based on bedside observation of shortterm effects by individual physicians. Only a few studies have evaluated shortand long-term clinical outcomes. Second, the most frequent clinical scenario of patients admitted with AHFS is CS1. Patients are often systemically euvolemic or hypovolemic because of a long-lasting history of increased blood pressure and chronic treatment with diuretics. Highdose diuretics in these patients may be detrimental.
Appropriate early diuretic use may differ depending on the characteristics of AHFS. Patients with fluid redistribution (CS1) should be considered differently from patients with worsening chronic fluid overload (CS2). The separation between these two profiles is not rigid, but this categorization may help provide a framework for diuretic therapy. This classification can be made based on the patient's history, clinical examination (signs of congestion), symptom severity (moderate decompensation, pulmonary edema, or cardiogenic shock), and blood pressure. The pathophysiology and therapeutic goals differ between these classifications. Thus, recognizing the appropriate patient profile is important, and it will help to guide the physician's early management strategy.
Diuretic prescription is primarily anecdotal. Only a few trials have studied the appropriateness of diuretic doses and methods of administration. These data suggest that low-dose furosemide (20 -40 mg or ‫-52.0ف‬ 0.5 mg/kg intravenously) is a reasonable initial therapy for most patients (53) (54) (55) . However, patients with hypotension and/or cardiogenic shock may require less aggressive diuresis. Patients with chronic heart failure on highdose diuretic therapy (CS2), patients with primarily right-sided heart failure (CS5), or patients with renal dysfunction may require higher doses or continuous diuretic infusion. Metolazone is also an option in patients with renal dysfunction owing to its additional, synergistic action on the proximal tubule (56) .
Variables for adjusting diuretic therapy have not been established. In general, the lowest dose should be used that produces the desired clinical effect. In chronic heart failure, diuretic therapy is titrated according to fluid balance and the resolution of signs and symptoms. These targets may be insensitive estimates of volume status during the initial management period for AHFS, especially in obese patients or those with other comorbidities.
The onset of diuresis may not occur until 30 -120 mins after administration; thus, urine output alone is not an ideal therapeutic target. Dyspnea, global patient status, respiratory rate, oxygen saturation, and need for intubation are better targets, especially in critically ill patients. Diuretic resistance and diuretic adaptation are important problems in patients with chronic heart failure, but their significance is limited in the initial management of AHFS patients. Patients with diuretic resistance may require higher diuretic doses or combination diuretics with different mechanisms of action. Loop diuretics may increase the neurohormonal cascade, which is detrimental to heart failure patients (57) .
Vasodilators
Group Recommendation
• Nitrate therapy is recommended in CS1, CS2, and CS4 if SBP is Ͼ110 mm Hg. The blood pressure below which nitrates should not be used varies among patients and clinical settings.
• If available, it is recommended to administer nitroglycerin spray sublingually before admission (prehospital) or in the ED.
• The initial recommended dose of intravenous nitroglycerin is 10 -20 g/min, increased in increments of 5-10 g/min every 3-5 mins as needed.
• Slow titration of intravenous nitrates and frequent blood pressure measurement is recommended to avoid large decreases in SBP.
• An arterial catheter is not required for monitoring nitrate therapy.
• Vasodilators are not recommended as first-line therapy in CS3.
• Nesiritide can decrease pulmonary artery occlusion pressure and improve dyspnea in acute heart failure, but it is currently a second-line agent due to concerns about deleterious effects on renal function and outcome.
• Calcium antagonists are not recommended in AHFS during the first 0 -12 hrs.
Based on registry data, the majority of AHFS patients present with increased left ventricular filling pressure and high or normal blood pressure (CS1 and CS2); only a minority present with low blood pressure or cardiogenic shock (CS3) (17, 58, 59 ). Patients with CS1 or CS2 are ideal candidates for early initiation of vasodilator therapy. Acute therapy with vasodilators can improve both hemodynamics and symptoms.
Vasodilators are usually given in conjunction with diuretics, although much of the acute effect of loop diuretics may be due to venodilation (60) . One small randomized study suggested that highdose nitrates plus low-dose furosemide were more effective than low-dose nitrates plus high-dose furosemide in acute pulmonary edema (53) . Currently available vasodilators include nitrates, nitroprusside, and nesiritide.
Nitrates include nitroglycerin, isosorbide mononitrate, and isosorbide dinitrate. Nitrates relieve pulmonary congestion primarily through direct venodilation. At higher doses, coronary artery dilation and increased collateral blood flow may decrease ischemia, an effect that is often desirable given the high incidence of coronary artery disease in heart failure patients. In AHFS, intravenous nitroglycerin is preferred. The initial recommended dose is 10 -20 g/min, and it is increased in increments of 5 g/min every 3-5 mins as needed. Frequent titration should be used to achieve goals rapidly without lowering blood pressure too precipitously. Tachyphylaxis is common, necessitating incremental dosing. The major adverse effects of nitrates are hypotension (mean blood pressure should remain Ͼ70 mm Hg) and headache.
Nitroprusside is a balanced arterial and venous vasodilator with a very short half-life, facilitating rapid titration. Afterload reduction lowers blood pressure and can increase stroke volume. Nitroprusside may be used in patients not responding to nitroglycerin. Nitroprusside is given by continuous intravenous infusion, starting at 0.1-0.2 g/kg/min and increased every 5 mins to achieve hemodynamic goals (blood pressure control or 20% to 50% decrease in occlusion pressure and/or 20% to 40% increase in cardiac output). Coronary steal is a concern in patients with ischemia, and nitroglycerin is preferred in these patients. Nitroprusside has been associated with increased mortality in AMI patients who received it within the first 9 hrs after the AMI (61). Thus, nitroprusside should be avoided in CS4. The major complication of nitroprusside therapy is hypotension. Toxicity may also occur from accumulation of cyanide or thiocyanate, usually in patients with renal insufficiency receiving high doses for Ն24 hrs.
Nesiritide, a recombinant form of human B-type natriuretic peptide, is a venous and arterial vasodilator that may also potentiate the effect of diuretics. It is given intravenously as a 2-g/kg bolus followed by a 0.01-g/kg/min infusion. In the VMAC trial, nesiritide lowered pulmonary artery occlusion pressure significantly more than either intravenous nitroglycerin or placebo at the 3-hr time point, and it improved dyspnea compared with placebo (4). However, the doses of nitroglycerin reached in the VMAC trial were lower than those typically used in clinical practice. Although nesiritide has natriuretic effects, it has not been shown to improve either glomerular filtration rate or renal plasma flow (62) . Hypotension is the most common side effect. In addition, meta-analyses of data from VMAC and other trials have suggested that nesiritide may worsen renal function and decrease survival at 30 days compared with conventional therapies (63, 64) . Resolution of these concerns awaits completion of appropriately powered prospective clinical trials. In contrast to other agents, blood levels of nesiritide do not rapidly decrease after drug discontinuation. Intravenous ACE inhibitors are not recommended in the early AHFS setting, particularly in patients with ischemic chest pain (65) .
Cardiac Enhancers and Vasoconstrictors
Group Recommendations
• Inotropes are used in a small number of patients, mainly with CS3. They are not recommended in CS1 and should be used in selected patients with CS2 or CS4.
• Traditional inotropes (dobutamine, milrinone) or the new inodilator levosimendan (where available) may be used early in patients with evidence of poor organ perfusion (patient is cold, clammy, or vasoconstricted or the patient has renal impairment, liver dysfunction, or impaired mentation) and low cardiac output, low SBP, and high filling pressures (as detected by physical examination and symptoms) who are not responding to other therapies.
• If no improvement in perfusion is observed, then advanced hemodynamic monitoring should be used. If blood pressure remains low (Ͻ100 mm Hg), then a vasoconstrictor should be considered after optimizing preload. Norepinephrine is the recommended vasoconstrictor in AHFS.
Traditional Inotropes. Inotropes are a traditional component of the AHFS treatment strategy. The most common inotropes in clinical practice include dobutamine and milrinone, but dopamine is also available. Traditional inotropes are no longer recognized as first-line, acute therapy for the majority of AHFS patients, and data from ADHERE, OPTI-MIZE, and Euro Heart Failure Survey II indicate that traditional inotropes are used in approximately 10% of AHFS admissions (1, 9, 66) . The OPTIME-CHF study found no benefit for milrinone in 949 patients hospitalized for worsening heart failure (2). A higher risk of arrhythmias was observed, and patients with ischemic etiology who were randomized to milrinone had worse outcomes (67, 68) . Patients were excluded if they required inotropic therapy; thus, the OP-TIME-CHF population did not include low-output/hypoperfused patients. A retrospective analysis from the ADHERE registry also suggested that inotropes should be avoided in the majority of AHFS patients. In this analysis of Ͼ65,180 patient cases, patients treated with either dobutamine or milrinone had significantly increased risk of in-hospital mortality compared with nitroglycerin or nesiritide after adjustment for covariates and propensity score (9) .
Early use of inotropic therapy may be appropriate in patients presenting in cardiogenic shock or with evidence of low output who are not responding to other therapies (7) . These patients may include those with SBP Ͻ85-90 mm Hg or evidence of organ hypoperfusion, including patients who are cold, clammy, or vasoconstricted. Renal impairment, liver dysfunction, and impaired mentation are also possible signs of hypoperfusion. As discussed, these patients account for the minority of AHFS hospitalizations. Inotropes may stabilize patients at risk of progressive hemodynamic collapse or serve as a life-sustaining bridge to more definitive therapy, such as mechanical circulatory support, ventricular assist devices, or cardiac transplant.
Levosimendan. Levosimendan is a novel calcium sensitizer that improves cardiac contractility by binding to troponin-C in cardiomyocytes. The significant vasodilatory properties of levosimendan are mediated through adenosine triphosphate-sensitive potassium channels, causing peripheral arterial and venous dilation and increasing coronary flow reserve (69) . Levosimendan has beneficial hemodynamic and clinical effects in patients with AHFS, and it is safe in ACS (3, 70, 71) . In the REVIVE trial, levosi-mendan significantly improved a composite of clinical signs and symptoms of AHFS compared with placebo over 5 days as assessed by patients and their physicians (5). In the SURVIVE study comparing levosimendan and dobutamine, a statistically significant improvement in survival for levosimendan-treated patients was seen early, especially in patients chronically treated with a ␤-blocker and in patients with prior heart failure, but it was not evident in 180-day survival (3) .
In countries where it is available, early levosimendan infusion can be considered for patients who remain symptomatic with dyspnea at rest despite initial therapy, particularly those chronically treated with ␤-blockers. Levosimendan may be initiated in patients with SBP Ͼ100 mm Hg with a bolus infusion dose of 6 -12 g/kg for 10 mins. This bolus dose should be lowered in patients with less pronounced fluid overload, such as those with de novo, new-onset AHFS. The initial rate of continuous infusion is typically 0.1 g/kg/min. In patients with SBP Ͼ85 and Ͻ100 mm Hg, the infusion should be started without a bolus dose to avoid hypotension. Levosimendan is not recommended for patients with SBP Ͻ85 mm Hg, although it has been used in combination with vasopressors, most often norepinephrine, in selected patients (3) .
Vasoconstrictors. Norepinephrine is recommended alone or in combination with an inotrope or cardiac enhancer in CS3 and CS6 in order to increase SBP in the situation of persistent organ hypoperfusion (e.g., low urine output clearly related to low blood pressure). The recommended dose is 0.2-1.0 g/kg/min. It may be started on a peripheral catheter, but a central catheter should be placed for its infusion as soon as feasible. Epinephrine is not recommended as firstline therapy, even in CS3. It is used as rescue therapy in cardiac arrest. There is no evidence of a renal benefit with lowdose dopamine.
Device Therapy
Group Recommendations • Device therapy should only be recommended when there is potential for myocardial recovery with or without intervention.
• Initiate the transfer process within the first 12 hrs in patients who have an indication for device therapy if device resources are not locally available.
• Consider early mechanical intervention in the following situations: blood pressure is not sustained Ͼ80 mm Hg in spite of inotropes; urine output is Ͻ30 mL/hr (or Ͻ0.5 mL/kg/min); skin is cool and mottled; oxygen saturation is dropping; there is ongoing ischemia.
• Intraaortic balloon pump is the first-line intervention.
• Ultrafiltration may be considered in patients who fail to respond to diuretic therapy
Early mechanical device therapy may be useful in patients who have not responded to other therapies during the first 6 -12 hrs after presentation. Patients who may be candidates for device therapy include those with severe and persistent hypotension or hypoperfusion despite the use of inotropes, urine output Ͻ30 mL/hr, decreasing oxygen saturation, persistent ischemia, or cold or mottled skin. When implemented early, the use of these devices may promote recovery in some patients.
IABP is the first-line device for these patients. It can be rapidly placed in the cardiac catheterization laboratory or in the CCU/ICU. It is associated with some risks, including compromised blood flow to the leg and dissection (particularly in patients with peripheral vascular disease). IABP only provides a temporary solution for AHFS. IABP may be implemented more quickly in patients with suspected ongoing ischemia.
Left ventricular assist devices will not generally be used within the first 6 -12 hrs of an AHFS presentation. Data from ADHERE indicate that Ͻ1% of patients hospitalized for AHFS receive left ventricular assist devices during the entire hospital stay; thus, their utility during the early phase is relatively low and should be further defined.
Managing Comorbidities
The majority of patients with AHFS have multiple comorbidities. These conditions may contribute to the development of AHFS, and they should be controlled as soon as possible after presentation. Examples include atrial fibrillation with rapid ventricular response, ventricular arrhythmias, bradycardia, severe anemia, and infection. In addition, concomitant medications can exacerbate heart failure and precipitate AHFS. These medications should be stopped immediately after presentation. Examples include nonsteroidal antiinflammatory drugs, cyclooxygenase-2 inhibitors, thiazelinediones, sympathomimetics, tricyclic antidepressants, class I and III antiarrhythmics (except amiodarone), and nondihydropyridine calcium channel blockers.
Management of Chronic Heart Failure Medications During AHFS Episode
Group Recommendations • Beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or aldosterone antagonists should be continued at the highest tolerated dose unless the patient has symptomatic hypotension (SBP Ͻ90 mm Hg), is in cardiogenic shock, or has significant hyperkalemia (ACE inhibitors, angiotensin receptor blockers, aldosterone antagonists) (K Ͼ5 mmol/L).
Time Course for Symptomatic Improvement in AHFS
Few data are available for CS1, but a clinical goal is to improve dyspnea by 3-6 hrs. The majority of data are from patients with CS2 (VMAC, REVIVE) (4, 5) . In these studies, dyspnea began to improve at 3 hrs, and it continued to improve until 48 hrs. Most patients (Ͼ70%) improved within the first 24 hrs. In these studies, patient global assessment (wellbeing) roughly matched dyspnea improvement. Symptomatic improvement in patients with CS3 and CS5 generally occurs after 48 hrs. However, in the more critically ill patients or in the patients with CS4, efficacy markers other than symptomatic improvement are needed. For example, the symptomatic improvement in CS4 primarily depends on percutaneous intervention results.
The average hospital length of stay for patients with CS1 is approximately 4 days in the United States and 9 -11 days in Europe. Most registries involved patients who would fit into the CS1 category, so little information on length of stay is available for the other clinical scenarios. However, the EFICA registry enrolled a sicker population who would most likely be classified as CS2 or CS3. Length of stay in EFICA ranged from 14.5 to 15.1 days, depending on the presence of cardiogenic shock (1, 5, 17, 58, 59, 66) .
Regulatory View on Studies in the Early Management of AHFS
The basic regulatory requirements for a drug in AHFS are to demonstrate predictable favorable hemodynamic effects and a clear clinical benefit, with no shortor long-term safety concerns. The immediate treatment objectives for AHFS are to relieve symptoms and to improve the hemodynamic condition. These short-term benefits should also be accompanied by favorable effects on longer term outcomes.
Hemodynamic improvement has traditionally been the efficacy marker for AHFS therapies. However, most therapies tested have not targeted the initial 6 -12 hrs after presentation (72) . Dyspnea is the dominant symptom in AHFS, and dyspnea improvement should be observed in conjunction with hemodynamic improvement. Patients with AHFS have a very poor prognosis. In addition to acute symptomatic and hemodynamic improvement, an effective drug for AHFS should also provide longer term benefit. From a regulatory perspective, total mortality is the preferred primary efficacy end point. Dyspnea improvement with reduction in pulmonary artery occlusion pressure, from either one or several studies, would also be considered acceptable evidence for efficacy provided deleterious effects on mortality and morbidity, both immediate and delayed, are ruled out. Hemodynamic findings are useful and needed, but they are not enough to form the sole basis for drug approval (72) .
Potential safety issues related to AHFS therapies include life-threatening arrhythmias, hypotension, myocardial ischemia, renal dysfunction, and sudden death. Increased short-or medium-term mortality has been reported with several agents (72) . Therefore, 6-month mortality data are required to exclude the possibility of a deleterious effect, even if the claim is only made for symptomatic benefit.
SUMMARY
Patients presenting with AHFS are a complex and heterogenous population at high risk of short-term morbidity and mortality. Early classification of patients according to their clinical presentation is a key step in determining the appropriate initial treatment. We proposed five clinical scenarios that physicians can use to identify an initial therapeutic approach. These categories identify patients according to the primary pathophysiologic problem, so that early, goal-directed therapy can be implemented. Early initiation of diagnostic and goal-directed treatment strategies may be a key factor in improving patient outcomes. Early and frequent reassessment is also imperative so that adjustments in the initial therapeutic approach can be made as clinically indicated. These recommendations may serve as a stimulus for much-needed research on early treatment initiation in patients with AHFS. The rapid treatment approach may prove to be an effective intervention for the management of AHFS.
